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The aim of the present study was to analyse the eﬀect of antiretroviral (ARV) therapy and single antiretroviral drugs on
cerebrospinal fluid (CSF) HIV-RNA burden in HIV-infected patients aﬀected by neurological disorders enrolled in a multicentric
Italian cohort. ARVs were considered “neuroactive” from literature reports. Three hundred sixty-three HIV-positive patients with
available data from paired plasma and CSF samples, were selected. One hundred twenty patients (33.1%) were taking ARVs at
diagnosis of neurological disorder. Mean CSF HIV-RNA was significantly higher in naı¨ve than in experienced patients, and in
patients not taking ARV than in those on ARV. A linear correlation between CSF HIV-RNA levels and number of neuroactive
drugs included in the regimen was also found (r = −0.44, P < 0.001). Low -plasma HIV-RNA and the lack of neurocognitive
impairment resulted in independently associated to undetectable HIV-RNA. Taking nevirapine or efavirenz, or regimen including
NNRTI, NNRTI plus PI or boosted PI, was independently associated to an increased probability to have undetectable HIV-RNA in
CSF. The inclusion of two or three neuroactive drugs in the ARV regimen was independently associated to undetectable viral load
in CSF. Our data could be helpful in identifying ARV regimens able to better control HIV replication in the CNS sanctuary, and
could be a historical reference for further analyses.
1. Introduction
One of the major concerns about antiretroviral (ARV)
therapy is the question of whether current ARV regimens are
eﬀective in suppressing HIV-1 replication in the central ner-
vous system (CNS) as well as in plasma. CNS is considered
one of the anatomic reservoirs of HIV replication, sites in
which the cellular HIV replication has a longer half-life [1, 2].
HIV dynamics in CNS and plasma can evolve independently,
leading to virologic compartmentalization of HIV infection
in the CNS [3]. It is well known that HIV can evolve and
replicate in neurological compartment independently from
plasma and the virological response in these two diﬀerent
compartments can be quite diﬀerent [3–5]. Moreover, a
residual HIV replication in CNS and persistent intrathecal
immune activation can be detected also in patients on ARV
[6, 7].
To assess the replication of HIV in CNS is not easy. The
levels of HIV-1 RNA in cerebrospinal fluid (CSF) has been
considered an indirect measure to assess active infection in
brain tissue and a biological marker of HIV infection, as
well as in plasma [8]. The diagnostic and prognostic role
of the detection of HIV-1 RNA in CSF for the development
of neuropsychological impairment has been evidenced in
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HIV-infected patients [9–11]. However, in the highly active
antiretroviral therapy (HAART) era the relationship between
CSF HIV-RNA levels and neurocognitive impairment seems
to be lost [12] and biological markers of brain damage are
lacking.
The strong beneficial eﬀect of the potent antiretroviral
regimens on disease progression is clearly documented [13,
14], but the eﬀect on the CNS and the protective role
against neurologic complication of HIV infection is less
evident. In the last years, a marked decline of neurologic
complications has been observed [15, 16]. A decrease in
the incidence of HIV-associated neurocognitive impairment
has been also registered, while its prevalence has risen [17].
Cumulating evidences indicate that a relevant proportion
of HIV-infected patients continue to present neurocognitive
impairment despite the treatment with HAART and that
currently available ARV regimens are often inadequate to
treat HIV-associated neurocognitive impairment [18].
HAART is demonstrated to eﬀectively reduce HIV-1
RNA levels in CSF [19, 20], but the neuroactive eﬀect of
antiretroviral drugs and the protective role of diﬀerent drug
classes in patients treated with HAART has to be conclusively
defined.
The aim of the present study was to analyse the eﬀect of
antiretroviral therapy and single antiretroviral drugs on CSF
HIV-1 RNA burden in a large cohort study group of HIV-
infected patients aﬀected by neurological disorders and to
identify factors related to undetectable levels of CSF HIV-1
RNA in such cohort.
2. Methods
To analyse the eﬀect of antiretroviral drugs, drug classes, and
number of CNS-penetrating drugs onHIV-RNA load in CSF,
a large group of HIV-infected patients aﬀected by neurolog-
ical disorders enrolled in the Italian Registry Investigative
NeuroAIDS (IRINA) was studied. IRINA is a longitudinal,
multicentric cohort study carried out in 45 Italian centres
of infectious diseases, that since 2000 enrols HIV-infected
patients aﬀected by neurological disorders. In particular, the
registry collects demographic and epidemiologic variables,
natural history of HIV infection, antiretroviral therapy,
clinical and radiological features, diagnostic criteria for
neurological diagnosis, and virological and immunological
parameters. Patients with paired CSF and plasma data
available were included in the present study and were
considered for the analysis. HIV-RNA levels in plasma and
CSF were quantified by branched-DNA (Bayer, detection
limit of 50 copies/mL, 1.69 log10), RT-PCR (Amplicor Roche
Diagnostics, detection limit 50 copies/mL) or nucleic acid
sequence-based amplification (NASBA) (Nuclisens HIV-1
QT assay Organon Teknika, detection limit of 80 (1.90
log10) copies/mL), depending on the assay used by each
center. To account for the diﬀerence between NASBA and
RT-PCR in HIV RNA quantification, values of HIV RNA
by NASBA assay were divided by two. For the analysis,
all HIV-RNA levels were transformed into log10 values.
For the statistical analysis, CSF HIV-RNA were considered
“undetectable” if the viral load was below the detection limit
of the tool used.
The statistical analysis was performed including patients
taking the drugs for which we have a larger case number of
plasma-CSF paired samples.
Antiretrovirals known to have high level of penetration
in CSF or to eﬀectively suppress HIV-RNA in CSF from liter-
ature reports, were considered “neuroactive drugs.” Among
the antiretrovirals prescribed to the study patients, the
neuroactive drugs included: zidovudine, stavudine, lamivu-
dine, abacavir, nevirapine, efavirenz, indinavir, lopinavir
[21–30]. Lopinavir was always administered associated to a
boost of ritonavir at recommended doses. Since indinavir
was administered with or without the boost of ritonavir,
boosted indinavir was considered as a diﬀerent regimen from
unboosted one.
Logistic regression was used to determine predictive
factors of undetectable CSF viral load. Multivariable analysis
was performed fitting three diﬀerent models including
variables related to antiretroviral therapy: in the first model
the eﬀect of each single drug included in the antiretroviral
regimen was analyzed; in the second model the eﬀect of
diﬀerent drug regimens was analyzed using the follow-
ing categorization criteria: unboosted Protease Inhibitors
PIs-, boosted PIs-, Non-Nucleoside-reverse-trascriptase-
inhibitors- (NNRTIs-), NNRTIs-plus-PIs-, only-nucleoside-
reverse-trascriptase-inhibitors- (NRTIs-) based regimens, or
no therapy; in the third model the eﬀect of the number
of neuroactive drugs, as defined above, was analyzed. The
Student t-test was employed to compare values of CSF HIV-
RNA in diﬀerent groups of patients (naı¨ve-experienced, on
HAART-no HAART). Correlation between log10 CSF HIV-
RNA and number of neuroactive drugs was calculated using
Pearson correlation coeﬃcient r. All statistical analyses were
performed by SPSS (version 11.0.1) for Windows (SPSS,
Chicago, Illinois, USA). P values < 0.05 were considered
statistically significant.
3. Results and Discussion
3.1. Results. Three hundred sixty-threeHIV-positive patients
aﬀected by neurological disorders and enrolled in IRINA
Study, with available data from paired plasma and CSF
samples, were selected for the present analysis. General char-
acteristics of the patients included were reported in Table 1.
Median CD4 count, plasma, and CSF HIV-1 RNA were
71 cell× 109/L (IQR: 22–162), 4.98 log10c/mL (3.81–5.44)
and 3.63 log10c/mL (2.17–4.83), respectively. In 16.5%
of patients CSF HIV-RNA was undetectable. Neurologic
disorders includedHIV encephalopathy (28.4%), Progressive
Multifocal Leucoenkephalopathy (15.4%); encephalopathies
of unknown origin (10.2%); Toxoplasmic encephalitis
(9.9%); cryptococcosis (9.6%); cerebral lymphoma (5%);
Tuberculous meningitis (2.8%); other diseases (18.7%).
Regarding antiretroviral (ARV) therapy exposure, 182
(50.1%) patients were ARV experienced and 120 (33.1%)
were taking ARV therapy at diagnosis of opportunistic or
neoplastic neurological disorder. The frequency of each
ARV agent included in the HAART regimen were as
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Table 1: General characteristics of the 363 HIV-positive patients
included in the study.
Characteristics Patients= 363
Male gender (n, %) 281 (77.4%)
Age, median (years) 41 (IQR, 36–46)
HIV transmission route (n, %)
(i) IVDU 157 (43.3%)
(ii) MSM 46 (12.7%)
(iii) Heterosexual 111 (30.5%)
(iv) Other/unknown 49 (13.5%)
Previous AIDS defining event (n, %) 109 (30.0%)
CD4 cell count, median (cell/mm3) 71 (IQR, 22–162)
Plasma HIV-1 RNA, median
(log10cp/mL)
4.98 (IQR, 3.81–5.44)
CSF HIV-1 RNA, median (log10cp/mL) 3.63 (IQR, 2.17–4.83)
Undetectable CSF HIV-RNA (n, %) 60 (16.5%)
Experienced to antiretroviral therapy
(n, %)
182 (50.1%)
Experienced on ARV at neurological
diagnosis (n, %)
120 (33.1%)
Time on HAART, median (months) 16 (IQR, 5–41)
>6 months on HAART before diagnosis
(n, %)
118 (32.5%)
Cognitive symptoms 213 (58.7%)
Abnormal mental status 90 (24.8%)
Cerebral atrophy 137 (37.7%)
Neurological disorders
(i) HIVE 103 (28.4%)
(ii) PML 56 (15.4%)
(iii) PCNSL 18 (5.0%)
(iv) TE 36 (9.9%)
(v) EUO 37 (10.2%)
(vi) CM/TB 45 (12.4%)
(vii) Other diseases 68 (18.7%)
IVDU: intravenous drug users, MSM: men who have sex with men,
CSF: cerebrospinal fluid; HIVE: HIV encephalopathy; PML: progressive
multifocal leucoencephalopathy; PCNSL: primary central nervous sys-
tem lymphoma; TE: toxoplasmic encephalitis; EUO: encephalopathies of
unknown origin; CM: cryptococcosis; TB: CNS tuberculosis/tubercular
meningitis.
follows: zidovudine 47 patients (12.9%), didanosine 23
patients (6.3%), stavudine 60 patients (16.5%), lamivudine
93 patients (25.6%), abacavir 16 patients (4.4%), nevirapine
14 (3.9%), 26 efavirenz patients (7.2%), indinavir 15 patients
(4.1%), ritonavir-boosted indinavir 8 patients (2.2%), nel-
finavir 25 patients (6.9%), ritonavir-boosted lopinavir 17
patients (4.7%). Regarding drug regimens, 37 (10.2%)
patients were taking unboosted PIs-, 30 (8.3%) boosted PIs-,
31 (8.5%) NNRTIs-, 8 (2.2%) NNRTIs plus PIs-, and 14
(3.9%) NRTIs-based regimens.
Eight patients (2.2%) were taking one neuroactive drug,
as above defined, 45 (12.4%) were taking two neuroactive
drugs, and 67 (18.5%) were taking three or four neuroactive
drugs.
Mean CSF HIV-1 RNA was significantly higher in
naı¨ve (4.3 (SD: ±1.3) log10c/mL) than in experienced (3.2
(±1.2) log10c/mL) patients (P < 0.001, Student t-test).
Similarly, mean CSF HIV-1 RNA was significantly higher
in patients not taking ARV therapy (4.2 (±1.2) log10c/mL)
than in patients on ARV therapy (2.9 (±1.1) log10c/mL)
(P < 0.001, t-Student test). A linear correlation between
the CSF HIV-1 RNA levels and the number of neuroactive
drugs included in the HAART regimen was also found
(r = −0.44, P < 0.001) (Figure 1). Furthermore, analyzing
the eﬀectiveness of antiretrovirals included in the patients’
regimens using the penetration score proposed by Letendre
et al. [31], the significant correlation between HIV-1 RNA
load in CSF and the CNS penetration-eﬀectiveness score was
confirmed (r = −0.43, P < 0.001).
Low plasmaHIV-RNA and the absence of neurocognitive
impairment resulted in independently associated to unde-
tectable HIV-RNA levels in all the three models of analysis
employed (Table 2). A significant correlation between HIV-
1 RNA load and the evidence of neurocognitive impairment
was also found (r = 0.11, P < 0.041). Regarding ARV drugs,
taking nevirapine (OR: 4.46; 95% CI: 1.03–19.32, P = 0.045)
or efavirenz (OR: 4.87; 95% CI: 1.16–20.54, P = 0.031)
was independently associated to an increased probability to
have undetectable HIV-RNA levels in CSF. Regarding ARV
regimens, the use of a regimen including NNRTI (12.46
(3.28–47.41), P < 0.01), NNRTI plus PI (10.42 (1.59–68.46),
P = 0.015) or boosted PI (5.64 (1.31–24.25), P = 0.02)
was independently associated to an increased probability to
have undetectable HIV-RNA levels in CSF. Similarly, the
inclusion of two or three neuroactive drugs in the ARV
regimen was independently associated to undetectable viral
load in CSF (for two neuroactive drugs the adjusted OR
was 4.11 (95% CI: 1.22–13.79), P = 0.022, for three
neuroactive drugs the adjusted OR was 5.48 (1.94–15.48,
P = 0.001)). Furthermore, using the CNS penetration-
eﬀectiveness rank proposed by Letendre et al. [31] was
associated to a significant probability to obtain undetectable
HIV-1 RNA in CSF (OR 1.20 (per 1 score higher, 95% CI
1.07–1.35, P = 0.001)).
No eﬀect of neurologic disorders and of baseline CD4 cell
count on HIV control in plasma and CSF was observed.
Considering the subgroup of 120 patients taking HAART
at neurological diagnosis and antiretroviral classes (PI,
boosted PI, NNRTI, NNRTI plus PI, only NRTI) as cofactor,
NNRTI-containing regimen was the only predictive factor
of CSF undetectability (OR: 5.38; 95% CI: 1.52–19.00, PI-
regimen as reference).
3.2. Discussion. The goal of the long lasting therapeutic
strategy in HIV-infected patients must consider the complete
control of HIV replication not only in the periphery, but
also in the neurological compartment. This is especially true
for patients with neurological complications aﬀecting the
CNS. A lot of reasons can partially explain the particular
condition of CNS compartment: first of all, the presence of
the blood brain barrier (BBB) in the CNS, with the tight
junctions between the endothelial cells that make peculiar
the CNS from the point of an anatomic view, separating the
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Figure 1: Correlation between the HIV-RNA load in the cere-
brospinal fluid (CSF) (copies/mL) and the number of neuroactive
drugs included in the HAART regimen. r = −0.44, P < 0.001.
ARVs: antiretroviral drugs.
brain from the rest of the body. The CNS can be considered
a sanctuary of HIV infection, where drugs penetrate in
variable proportion. Some antiretrovirals penetrate less
eﬀectively, reaching sometimes inadequate concentrations.
Drug penetration is based on diﬀerent conditions: molecular
weight, lipid solubility and protein binding for diﬀusion,
active transport system, and drug eﬄux system. In presence
of low concentrations of drugs in CSF the replication of
HIV can continue. Some drugs are considered to have good
penetration in cerebral compartment and to have eﬃcacy on
controlling HIV replication [21–30].
The issue if the use of drugs having a good penetration
across the BBB is necessary to reach the control of HIV
replication also in CNS is currently not clear. It is also
questioned if a complete suppression of HIV viral load can
be reached in CSF and if it is possible to identify an optimal
antiretroviral therapy to obtain the complete control of HIV
replication in CSF.
The use of nucleotide analogues has been associated
to AIDS dementia decline in EUROSIDA cohort [15], but
only for zidovudine a controlled trial has demonstrated a
beneficial eﬀect on dementia complex [32].
Previous studies showed a better virological decline of
HIV-RNA in CSF using three or more drugs with good
penetration [19] and a higher number of CSF-penetrating
drugs [33–35]. The use of HAART was correlated to the
decline of HIV-RNA in CSF and to a better neurocognitive
performance [34, 36] in some patients, but the use of
single CSF penetrating HAART versus multiple has not
shown a marked benefit in psychomotor speed change in
nonadvanced patients [37]. In a previous study, we failed to
find a correlation between the neurocognitive performance
(NPZ8 score) and the number of penetrating drugs included
in the antiretroviral regimen in HIV-positive patients with a
good immunological level and stable HAART [38].
A penetration score has been proposed by Letendre et al.
[31] to evaluate whether the penetration of antiretrovirals
in the CNS is associated to lower CSF viral load. A numeric
penetration score was obtained summing the score assigned
to singular drugs included in the antiretroviral regimen
taken by patients, considering the published data on CSF
concentrations and chemical properties. Higher penetration
scores were strongly and independently associated with lower
CSF viral load also after adjusting for total number of
antiretrovirals and plasma viral load [31].
The data obtained from the present study, conducted
on a large cohort of HIV-infected patients, confirm that
antiretroviral therapy can determine a significant reduction
of HIV burden in CSF as documented by the lower HIV-
1 RNA load observed in antiretroviral experienced patients
compared to naı¨ve patients, and in HAART-treated patients
compared to non-HAART-treated patients, also in presence
of neurological disorders. Our data indicate that a higher
number of CNS penetrating ARVs or an higher CNS
penetration-eﬀectiveness score using Letendre classification
of ARVs correlated with lower CSF RNA levels (r = −0.44,
P < 0.001, r = −0.43, P < 0.001, resp.). Moreover,
the use of a higher number of CNS-penetrating drugs
enhances the probability to obtain undetectable level of
CSF HIV-RNA. Compared to regimens containing no CNS-
penetrating ARVs, the use of two (OR = 4.11; 95%CI = 1.22–
13.79) or at least three (OR = 5.48; 95% CI = 1.94–15.48)
penetrating CNS ARVs markedly improved the probability
of having a CSF HIV RNA level below the detection limit of
50 copies/mL.
Furthermore, we made an eﬀort to identify antiretroviral
schemes or agents that could improve HIV control in CSF.
Among specific ARVs, the use of nevirapine (OR = 4.46;
95% CI = 1.03–19.32) and efavirenz (OR = 4.87; 95%
CI = 1.16–20.54) showed the best correlations with the
probability of having CSFHIV RNA level below the detection
limit of 50 copies/mL. Among antiretroviral drug classes, the
exposure to NNRTIs (OR = 12.46; 95% CI = 3.28–47.4) and
boostered PI (OR = 5.64, 95% CI = 1.31–24.25) increases
the probability to reach undetectable levels of HIV-RNA in
CSF. Taken together these data indicate that the use of ARVs
with good penetration into the CNS increases the probability
of controlling HIV replication in CSF. Prospective study are
needed to confirm our data.
We are aware of potential limits of our study. First, we
know that the undetectable HIV load in CSF cannot fully
reflect controlled replication of HIV in the brain tissue.
Moreover, we have no data to support the hypotheses that
controlled HIV replication in CSF translates in neurocogni-
tive improvement in our study patients on HAART.
In recent years, a decreased frequency of HIV-related
neurological disorders was observed, and a lower number
of patients underwent lumbar puncture, so the number of
available paired CSF-plasma samples was lower. The analysis
here reported was limited to drugs for which we have a
larger case number of plasma-CSF paired samples. It does
not include new NRTIs, NNRTIs, PIs drugs and new classes,
as fusion and entry inhibitors or integrase inhibitors, more
recently introduced, that are very interesting to study, and
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it represents a limitation of the present study. Unfortunally,
because of the small number available for statistics, we were
not able to investigate these more recent drugs.
In conclusion, our data support the concept that the
inclusion of a higher number of CNS penetrating drugs is
associated with an increased probability of having unde-
tectable CSF HIV RNA levels in HIV-infected patients
aﬀected by neurological disorders. Our data could be helpful
in identifying ARV regimens able to better control HIV
replication in the CNS sanctuary and could be a historical
reference for further analyses regarding the “new antiretrovi-
ral drugs”.
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